Market research
NVCR Novocure Ltd
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 26.8571
- Dividend yield
- Not available
- Beta
- 0.99
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- JE00BYSS4X48
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 26.8571
- Dividend yield
- Not available
- Beta
- 0.99
About
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Research context
Novocure Ltd appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the NVCR discussion.
5 years, 7 months ago
NovoCure Limited is currently in a long term uptrend where the price is trading 16.8% above its 200 day moving average.
From a valuation standpoint, the stock is 97.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 29.4.
NovoCure Limited's total revenue rose by 45.1% to $144M since the same quarter in the previous year.
Its net income has increased by 15.4% to $5M since the same quarter in the previous year.
Finally, its free cash flow grew by 1121.4% to $48M since the same quarter in the previous year.
Based on the above factors, NovoCure Limited gets an overall score of 5/5.